CMMB
Chemomab Therapeutics Ltd.
Key Financials
Net Income
$-27646000
↓ 121.6%
Total Liabilities
$6.8M
↑ 136.9%
EPS (Diluted)
$0.12
↑ 101.7%
Shareholders' Equity
$36.2M
↓ 41.1%
Total Assets
$43.1M
↓ 33.1%
Operating Cash Flow
$-20370000.00
↓ 64.6%
Cash & Equivalents
$13.5M
↓ 11.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 3 | 4/10/2026 | View on SEC |
| 3 | 4/10/2026 | View on SEC |
| 3 | 4/10/2026 | View on SEC |
| 3 | 4/10/2026 | View on SEC |
| 3 | 4/10/2026 | View on SEC |
| 3 | 4/10/2026 | View on SEC |
| 3 | 3/31/2026 | View on SEC |
| 3 | 3/31/2026 | View on SEC |
| 20-F | 3/23/2026 | View on SEC |
| 6-K | 3/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CMMB |
| Company Name | Chemomab Therapeutics Ltd. |
| CIK | 1534248 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | L3 |
| Phone | 972-77-331-0156 |